The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review)
Oncology Letters · 16.09.2025 · 30 (5) · 1-20
DOI: 10.3892/ol.2025.15272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 16.09.2025. Verfasst von Mengyan Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Sorafenib, a multi-target tyrosine kinase inhibitor, is widely used for the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). The present review explores the potential of sorafenib combination therapy to overcome drug resistance, mitigate toxicity and enhance efficacy. Sorafenib inhibits tumor growth and angiogenesis but is often limited by rapid resistance development and severe side effects. Combination therapies involving inhibitors of the PI3K/AKT/mTOR pathway, oxidative stress and autophagy inhibitors show promise in improving antitumor efficacy, reducing resistance and lowering toxicity. However, challenges such as complex drug interactions, increased treatment costs and a lack of long-term clinical data remain. Future research should focus on personalized combination strategies, exploring new molecular targets and performing large-scale clinical trials to optimize the safety and efficacy of sorafenib combination therapies, ultimately advancing cancer treatment and improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China.
- Hebei Key Laboratory of Heart and Metabolism, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China.
- Department of Orthopedics, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China.
Zitieren
APA
Wei, M., Cao, Z., Dong, L., Wang, W., Wei, M., Ji, L., Duan, L., Sun, H., & Zheng, M. (2025). The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review). Oncology Letters, 30(5), 1-20. https://doi.org/10.3892/ol.2025.15272
Vancouver
Wei M, Cao Z, Dong L, Wang W, Wei M, Ji L, et al. The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review). Oncology Letters. 2025;30(5):1-20. doi:10.3892/ol.2025.15272
BibTeX
@article{Wei2025,
author = {Wei, Mengyan and Cao, Zelong and Dong, Liang and Wang, Wei and Wei, Mei and Ji, Lishuang and Duan, Linan and Sun, Hui and Zheng, Mingqi},
title = {The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review)},
journal = {Oncology Letters},
year = {2025},
volume = {30},
number = {5},
pages = {1--20},
doi = {10.3892/ol.2025.15272}
}
EUVIMED